Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.

Evestra, Inc.

Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer

To reduce the risk of breast cancer, a drug is periodically administered to young mammals before pregnancy in doses of about 1 microgram to 50 micrograms per kilogram of body weight. The drug: (1) competes with and displaces estradiol 17 beta from the mammary gland cells in an effective manner to prevent the possible formation of DNA-damaging epoxide estradiol metabolites; (2) binds to breast tissue to a greater extent than estradiol 17 beta; (3) induces terminal nonlactation differentiation of the mammary gland; (4) is nontoxic and noncarcinogenic; and (5) preferably does not cause anti-ovulatory activity. The drug is selected from a group of drugs including: (1) 4-OH estradiol; (2) d-equilenin; and (3) 17 alpha ethynyl estriol.

estriol/krūties vėžys

Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer

Prevention of mammary carcinoma

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu